- |||||||||| Goofice (elobixibat) / Eisai, Mochida, Ipsen
Phase classification: Study of A3309 in Patients With Dyslipidemia (clinicaltrials.gov) - Mar 7, 2024 P2, N=36, Completed, Phase classification: P1/2 --> P=N/A Phase classification: P2a --> P2
- |||||||||| Kanuma (sebelipase alfa) / AstraZeneca
Trial completion, Trial primary completion date: VITAL: Safety, Tolerability, Efficacy, Pharmacokinetics, and Pharmacodynamics of Sebelipase Alfa in Children With Growth Failure Due to Lysosomal Acid Lipase Deficiency (clinicaltrials.gov) - Jan 30, 2019 P2/3, N=9, Completed, Active, not recruiting --> Completed | N=820 --> 550 Active, not recruiting --> Completed | Trial primary completion date: Aug 2014 --> Jan 2018
- |||||||||| Trial completion, Trial completion date, Trial primary completion date: Stress and Sugar Synergy (clinicaltrials.gov) - Jan 16, 2019
P=N/A, N=23, Completed, Active, not recruiting --> Completed | Trial primary completion date: Aug 2014 --> Jan 2018 Active, not recruiting --> Completed | Trial completion date: Dec 2018 --> Dec 2016 | Trial primary completion date: Dec 2018 --> Dec 2016
- |||||||||| Trial completion: Cholic Acid for Hepatic Steatosis in Lipodystrophy (clinicaltrials.gov) - Jan 16, 2019
P2, N=18, Completed, Active, not recruiting --> Completed | Trial completion date: Dec 2018 --> Dec 2016 | Trial primary completion date: Dec 2018 --> Dec 2016 Active, not recruiting --> Completed
- |||||||||| Trial completion, Trial primary completion date: The CREATE Wellness Study (clinicaltrials.gov) - Oct 16, 2018
P=N/A, N=647, Completed, Phase classification: P1 --> P1/2 Active, not recruiting --> Completed | Trial primary completion date: Jun 2018 --> Sep 2018
- |||||||||| Trial completion, Phase classification, Enrollment change: Novel Therapies for Metabolic Complications of Lipodystrophies (clinicaltrials.gov) - Oct 16, 2018
P=N/A, N=4, Completed, Active, not recruiting --> Completed | Trial primary completion date: Jun 2018 --> Sep 2018 Recruiting --> Completed | Phase classification: P2/3 --> PN/A | N=72 --> 4
- |||||||||| Enrollment change, Trial completion date, Trial primary completion date: Low Carbohydrate Diet - Effect on Plasma Lipids and Metabolic Markers (clinicaltrials.gov) - Oct 10, 2018
P=N/A, N=30, Completed, Active, not recruiting --> Completed | Phase classification: P2 --> PN/A N=22 --> 30 | Trial completion date: Nov 2013 --> Sep 2017 | Trial primary completion date: Nov 2013 --> Sep 2017
- |||||||||| Galafold (migalastat) / Amicus
Trial termination, Monotherapy: Open-Label Phase 3 Long-Term Safety Study of Migalastat (clinicaltrials.gov) - Oct 2, 2018 P3, N=85, Terminated, Completed --> Terminated; The Sponsor (Amicus Therapeutics) terminated this study for logistical reasons. Completed --> Terminated; Amicus Therapeutics discontinued Study AT1001-041 for logistical reasons.
- |||||||||| fenofibrate nanoparticle formulation / Generic mfg.
Trial completion, Trial completion date, Trial primary completion date, Combination therapy, Monotherapy: Phase III Study of Rosuvastatin and Fenofibrate Versus Rosuvastatin in Mixed Dyslipidemia (clinicaltrials.gov) - Aug 24, 2018 P3, N=362, Completed, N=14 --> 9 Not yet recruiting --> Completed | Trial completion date: Mar 2016 --> Jun 2017 | Trial primary completion date: Mar 2016 --> Oct 2016
- |||||||||| Livalo (pitavastatin) / Kowa, Eli Lilly
Trial completion, Trial completion date, Trial initiation date, Trial primary completion date: SIPHON: to Evaluate the Safety and Efficacy of Pitavastatin in Patients With IFG and Hyperlipidemia (clinicaltrials.gov) - Mar 8, 2018 P4, N=313, Completed, Active, not recruiting --> Completed Active, not recruiting --> Completed | Trial completion date: Oct 2017 --> May 2017 | Initiation date: Jan 2014 --> Sep 2013 | Trial primary completion date: May 2016 --> May 2017
- |||||||||| Trial completion date: Detecting Dopaminergic Deficits in Individuals At-risk for Parkinsonism (clinicaltrials.gov) - Mar 3, 2018
P=N/A, N=60, Active, not recruiting, Active, not recruiting --> Completed | Trial completion date: Oct 2017 --> May 2017 | Initiation date: Jan 2014 --> Sep 2013 | Trial primary completion date: May 2016 --> May 2017 Trial completion date: Dec 2017 --> Dec 2018
- |||||||||| Trial completion, Enrollment change, Trial completion date, Trial initiation date, Trial primary completion date: Fabry Screening Study (clinicaltrials.gov) - Feb 13, 2018
P=N/A, N=2724, Completed, Trial primary completion date: Dec 2017 --> Jun 2017 Suspended --> Completed | N=5000 --> 2724 | Initiation date: Aug 2008 --> Jan 2009 | Trial primary completion date: Dec 2018 --> Apr 2013 | Trial completion date: Jan 2019 --> Dec 2017
- |||||||||| atorvastatin / Generic mfg.
Trial completion, Trial primary completion date: HDL PROTECT: The HDL Particle Protection Study (clinicaltrials.gov) - Feb 1, 2018 P4, N=16, Completed, Active, not recruiting --> Completed Recruiting --> Completed | Trial primary completion date: Dec 2014 --> May 2017
- |||||||||| Enrollment closed, Trial primary completion date: The CREATE Wellness Study (clinicaltrials.gov) - Jan 8, 2018
P=N/A, N=588, Active, not recruiting, Active, not recruiting --> Completed Recruiting --> Active, not recruiting | Trial primary completion date: Dec 2017 --> Jun 2018
- |||||||||| Trial completion, Enrollment change: Screening for Fabry Disease in a Pediatric Population at Risk (clinicaltrials.gov) - Dec 13, 2017
P=N/A, N=1422, Completed, Recruiting --> Active, not recruiting | Trial primary completion date: Dec 2017 --> Jun 2018 Active, not recruiting --> Completed | N=2000 --> 1422
- |||||||||| Trial completion: Soda and Milk Study (clinicaltrials.gov) - Nov 7, 2017
P=N/A, N=30, Completed, N=228 --> 68 | Recruiting --> Terminated; Study had a minor contingency that could not be resolved with the IRB. Active, not recruiting --> Completed
|